



Senate

General Assembly

File No. 559

February Session, 2018

Senate Bill No. 539

Senate, April 17, 2018

The Committee on Finance, Revenue and Bonding reported through SEN. FONFARA of the 1st Dist. and SEN. FRANTZ, L. of the 36th Dist., Chairpersons of the Committee on the part of the Senate, that the bill ought to pass.

AN ACT CONCERNING A WORKING GROUP TO DEVELOP A PLAN TO FOSTER THE MICROBIOME SECTOR IN THE STATE.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 132 of public act 17-2 of the June special session is
2 repealed and the following is substituted in lieu thereof (*Effective from*
3 *passage*):

4 (a) There is established a working group to devise a roadmap to
5 establish the state as a national leader in the development and
6 commercialization of new microbiome-based treatments, products and
7 services. In devising the roadmap, the working group shall examine all
8 of the following, in addition to any other initiatives the working group
9 deems appropriate and necessary to accomplish its duties under this
10 section:

11 (1) Best practices of states and institutions recognized as leaders in
12 the microbiome field, including, but not limited to, the University of

13 California, San Diego Center for Microbiome Innovation, its associated
14 initiatives and partners and its business networks and connections;

15 (2) The relative importance of and interrelationship between pure
16 microbiome research and commercialization activity, and best
17 practices to stimulate both;

18 (3) Whether it would be in the best interest of the state to develop a
19 specialization or specializations within the human, animal or
20 environmental microbiome field or any subfield thereof;

21 (4) (A) The talent pool and skills necessary to establish the state as a
22 leader in the microbiome industry, (B) the educational curricula and
23 training levels required to fill such needs and the level at which public
24 and independent institutions of higher education in the state are
25 meeting such requirements, (C) the ability of the state to attract out-of-
26 state individuals with such talent and skills, and (D) a determination of
27 how to develop such talent and skills to the levels required to meet the
28 goals and requirements of this subsection, in terms of the skills
29 required, the needed number of skilled workers in the state and
30 specific academic and practical training recommended to be
31 strengthened at such institutions; and

32 (5) The strength and amount of academic expertise in the
33 microbiome field at public and independent institutions of higher
34 education in the state, including how aligned such expertise is with the
35 working group's roadmap, considering such institutions' plans to grow
36 and deepen such expertise and technology commercialization efforts
37 by faculty at such institutions.

38 (b) The working group shall consist of (1) the Commissioners of
39 Economic and Community Development, Public Health and Revenue
40 Services, or their designees, (2) the chairperson of the CTNext board of
41 directors or the chairperson's designee, (3) the president of The
42 University of Connecticut or the president's designee, (4) the dean of
43 The University of Connecticut School of Medicine or the dean's
44 designee, (5) the president of the Board of Regents for Higher

45 Education or the president's designee, and (6) the following, to be
46 appointed by the Governor: (A) One representative of an independent
47 institution of higher education in the state; (B) one representative of an
48 independent medical school in the state; (C) one representative from
49 Yale University or Yale University School of Medicine; (D) two
50 representatives of bioscience companies located in the state and in
51 business for five years or more; (E) two representatives of bioscience
52 companies located in the state and in business for less than five years;
53 (F) one representative of a venture capital firm located in the state; and
54 (G) one individual who represents hospitals in the state. The working
55 group may consult with industry stakeholders and representatives of
56 microbiome companies, representatives of educational and research
57 institutions that are focused on the microbiome sector, representatives
58 of the medical field who have expertise in the medical applications of
59 microbiome-based products and services and any other individuals or
60 representatives of fields the working group deems necessary or
61 appropriate to inform it on the microbiomes sector.

62 (c) The Governor shall select the chairperson of the working group
63 from among the members of the working group. Such chairperson
64 shall schedule the first meeting of the working group, which shall be
65 held not later than sixty days after the effective date of this section.

66 (d) The administrative staff of the joint standing committee of the
67 General Assembly having cognizance of matters relating to finance,
68 revenue and bonding shall serve as administrative staff of the task
69 force.

70 (e) Notwithstanding the provisions of section 2-15 of the general
71 statutes, no member of the working group shall receive mileage
72 reimbursement or a transportation allowance for traveling to or from a
73 meeting of the working group.

74 (f) Not later than January 1, [2018] 2019, the working group shall
75 submit a report, in accordance with section 11-4a of the general
76 statutes, of its roadmap developed pursuant to subsection (a) of this
77 section to the joint standing committees of the General Assembly

78 having cognizance of matters relating to finance, revenue and bonding,
 79 commerce and public health. The report shall include (1)
 80 recommendations for legislative and programmatic changes to
 81 effectuate the roadmap, (2) for each such recommended change, a
 82 proposed budget, listing options for full, medium and low funding
 83 levels, and (3) for each such recommended change, recommended
 84 measureable and achievable goals and a proposed timetable for
 85 accomplishing such change.

86 (g) Not later than February 1, [2018] 2019, the working group shall
 87 make a presentation of its report under subsection (e) of this section to
 88 the Governor and at a joint presentation to the joint standing
 89 committees of the General Assembly having cognizance of matters
 90 relating to finance, revenue and bonding, commerce and public health.

91 Sec. 2. Special act 17-16 is repealed. (*Effective from passage*)

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>from passage</i>	PA 17-2 of the June Sp. Sess., Sec. 132
Sec. 2	<i>from passage</i>	Repealer section

FIN *Joint Favorable*

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note***State Impact:*** None***Municipal Impact:*** None***Explanation***

The bill extends the reporting deadline of the previously established working group to devise a roadmap to establish the state as a national leader in the development and commercialization of new microbiome-based treatments. The working group shall submit its findings and recommendations and make a presentation to the finance, revenue and bonding committee as well as the public health committee by February 1, 2019.

This bill has no fiscal impact as PA 17-236 prohibits transportation allowances for task force members.

The Out Years***State Impact:*** None***Municipal Impact:*** None

OLR Bill Analysis

SB 539

AN ACT CONCERNING A WORKING GROUP TO DEVELOP A PLAN TO FOSTER THE MICROBIOME SECTOR IN THE STATE.

SUMMARY

The Office of Legislative Research does not analyze Special Acts.

COMMITTEE ACTION

Finance, Revenue and Bonding Committee

Joint Favorable

Yea 45 Nay 1 (04/05/2018)